These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38335180)

  • 21. Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer.
    Frantzi M; Heidegger I; Roesch MC; Gomez-Gomez E; Steiner E; Vlahou A; Mullen W; Guler I; Merseburger AS; Mischak H; Culig Z
    World J Urol; 2022 Sep; 40(9):2195-2203. PubMed ID: 35841414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4-10 ng/mL.
    Zhou Y; Li Y; Li X; Jiang M
    Biomed Res Int; 2017; 2017():2512536. PubMed ID: 28293631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
    Steuber T; Tennstedt P; Macagno A; Athanasiou A; Wittig A; Huber R; Golding B; Schiess R; Gillessen S
    BJU Int; 2019 May; 123(5):826-833. PubMed ID: 30216634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
    Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
    Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of prostate cancer biomarkers in undiagnosed men.
    Dani H; Loeb S
    Curr Opin Urol; 2017 May; 27(3):210-216. PubMed ID: 28212119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Likelihood of prostate cancer based on prostate-specific antigen density by MRI: retrospective analysis.
    Mueller-Lisse UG; Mueller-Lisse UL; Haller S; Schneede P; Scheidler JE; Schmeller N; Hofstetter AG; Reiser MF
    J Comput Assist Tomogr; 2002; 26(3):432-7. PubMed ID: 12016375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
    Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
    Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Lendínez-Cano G; Ojeda-Claro AV; Gómez-Gómez E; Morales Jimenez P; Flores Martin J; Dominguez JF; Amores J; Cozar JM; Bachiller J; Juárez A; Linares R; Garcia Galisteo E; Alvarez Ossorio JL; Requena Tapia MJ; Moreno Jimenez J; Medina Lopez RA;
    Prostate; 2021 Sep; 81(12):857-865. PubMed ID: 34184761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy.
    Lee WK; Lee S; Hong SK; Lee SE; Choi WS; Byun SS
    Int Braz J Urol; 2014; 40(4):484-92. PubMed ID: 25251953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
    Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
    Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of Prostate Biopsy Outcome.
    Juracek J; Madrzyk M; Trachtova K; Ruckova M; Bohosova J; Barth DA; Pichler M; Stanik M; Slaby O
    Cancer Genomics Proteomics; 2023; 20(3):308-316. PubMed ID: 37093688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
    Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
    Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
    Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
    Front Immunol; 2021; 12():786828. PubMed ID: 34975879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
    Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
    Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer.
    Wang F; Ren S; Chen R; Lu J; Shi X; Zhu Y; Zhang W; Jing T; Zhang C; Shen J; Xu C; Wang H; Wang H; Wang Y; Liu B; Li Y; Fang Z; Guo F; Qiao M; Wu C; Wei Q; Xu D; Shen D; Lu X; Gao X; Hou J; Sun Y
    Oncotarget; 2014 Nov; 5(22):11091-102. PubMed ID: 25526029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.